RxDoctor Payments Data

Colby James, APRN

Psychiatric/Mental Health · Layton, UTNPI 1578193926

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,571 and has fallen 57.9% since, to $1,082 in 2025. Among psychiatric/mental health clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,158in general payments, 2019–2025

Across 496 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Sunovion Pharmaceuticals Inc.$957
  • Otsuka America Pharmaceutical, Inc.$777
  • Alkermes, Inc.$492
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$8,146100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,158 in reported general payments places this provider in the 95th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$5,815
Medicare patients
23
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate47$159,272
FanaptIloperidone24$81,452
Abilify MaintenaAripiprazole20$52,925
ConcertaMethylphenidate Hcl12$10,421
Paliperidone ErPaliperidone14$8,217
AuvelityDextromethorphan Hbr/Bupropion11$6,591
Chlorpromazine Hcl17$5,041
Ziprasidone Hcl45$4,856
Lurasidone Hcl15$4,218
Olanzapine65$1,977
Quetiapine Fumarate98$1,959
Trazodone Hcl158$1,803
Risperidone37$1,485
Divalproex Sodium ErDivalproex Sodium49$1,472
Hydroxyzine Hcl65$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Concerta$1,237$169,69359 claims
Vanda Pharmaceuticals Inc.Fanapt$363$81,45224 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$777$52,92520 claims
Axsome Therapeutics, Inc.Auvelity$190$6,59111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →